International – CBD and transparency: Not all CBDs are the same

As the laws surrounding the use of cannabis and related products change, Barbara Brockway asks, how can cosmetics companies be sure that they are using the right ingredient from the right source?

CBD has already become a familiar term, despite people being unsure of the exact nature of CBD oils and their relationship to Cannabis sativa.

In April’s SPC article CBD & skin: A scientific history, Rouah Al-Wakeel introduced CBD and the endocannabinoid system (ECS), explaining how its primary function is to maintain the body’s equilibrium[1].

She went on to write about cannabinoids in skin, mentioning the many cannabinoid receptors found in skin and how skin naturally synthesises its own endocannabinoids (anandamide and 2-AG).

These two skin cannabinoids bind to skin cannabinoid receptors and surpress cellular proliferation, trigger cell differentiation and control the release of inflammatory mediators.

Skin endocannabinoids can also initiate lipid production and reduce pain and itching[2].

The current literature indicates that CBDs may be beneficial for acne and atopic dermatitis, however, studies tend to be small and so non-conclusive[3].

The shortage of authoritative studies has divided scientific opinion and left many toxicologists feeling that there is insufficient information on the pharmacokinetics and toxicity of topical CBD.

Dermal absorption of CBD from cosmetics, even after repeated use, would be expected to be low, because of its lipophilic nature, however more studies are needed to be certain.

To help address the need for good scientific information, The International Cannabis and Cannabinoids Institute (ICCI), has been established. It is bringing together global experts from academia, health care and industry to research the various uses of medical cannabis and investigate anecdotal claims about health benefits…